Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Saxagliptin
Drug ID BADD_D01992
Description Saxagliptin (rINN) is an orally active hypoglycemic (anti-diabetic drug) of the new dipeptidyl peptidase-4 (DPP-4) inhibitor class of drugs. FDA approved on July 31, 2009.
Indications and Usage Treatment of type 2 diabetes mellitus to improve glycemic control in combination with other agents or as monotherapy.
Marketing Status approved
ATC Code A10BH03
DrugBank ID DB06335
KEGG ID D08996
MeSH ID C502994
PubChem ID 11235729
TTD Drug ID D0K9MY
NDC Product Code 50193-4212; 0310-6100; 0310-6105; 11722-078; 0310-7100; 50370-0030; 55154-6931; 0310-7105
UNII 9GB927LAJW
Synonyms saxagliptin | 3-hydroxyadamantylglycine-4,5-methanoprolinenitrile hydrate | Onglyza | BMS 477118 | BMS477118 | BMS-477118
Chemical Information
Molecular Formula C18H25N3O2
CAS Registry Number 361442-04-8
SMILES C1C2CC2N(C1C#N)C(=O)C(C34CC5CC(C3)CC(C5)(C4)O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dehydration14.05.05.0010.001211%
Dermatitis23.03.04.002--Not Available
Dermatitis exfoliative10.01.01.004; 23.03.07.001--
Diabetes mellitus inadequate control14.06.01.004; 05.06.01.0040.001048%Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.11.04.0060.002815%
Drug eruption23.03.05.001; 10.01.01.005; 08.01.06.0150.000720%Not Available
Drug interaction08.06.03.0010.001211%Not Available
Dysgeusia07.14.03.001; 17.02.07.0030.000720%
Dyspepsia07.01.02.0010.000720%
Dysphagia07.01.06.0030.002095%
Face oedema10.01.05.002; 08.01.07.003; 23.04.01.004--
Fatigue08.01.01.002--
Flatulence07.01.04.002--
Fluid retention20.01.02.003; 14.05.06.0020.001670%Not Available
Fracture15.08.02.001; 12.04.02.001--
Gait disturbance08.01.02.002; 15.03.05.013; 17.02.05.0160.000327%
Gastritis07.08.02.001--
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Headache17.14.01.001--
Hepatic function abnormal09.01.02.0010.000655%Not Available
Hepatocellular injury09.01.07.0080.000327%Not Available
Hyperglycaemia14.06.02.002; 05.06.02.0020.001211%
Hypersensitivity10.01.03.003--
Hypertriglyceridaemia14.08.02.001--
Hyperuricaemia14.09.01.0030.000327%
Hypocalcaemia14.04.01.0040.000491%
Hypoglycaemia05.06.03.001; 14.06.03.0010.001931%
Hypoglycaemic coma17.02.09.005; 14.06.03.004; 05.06.03.0040.000491%Not Available
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene